Synta Pharmaceuticals Corp. management are betting that despite a drop-off in efficacy seen in one-year follow-up data for the Phase IIb/III GALAXY-1 trial of its ganetespib in second-line non-small-cell lung cancer, the protocol changes made for its GALAXY-2 trial should deliver positive pivotal results for the heat shock protein 90 (HSP90) inhibitor.
At one-year follow-up, the survival data from GALAXY-1 were not as robust as were reported in a June update, the...